FDA Inspection 1052335 — Barox Co., Ltd.

Barox Co., Ltd. — FEI 3010166805

The FDA completed an inspection of Barox Co., Ltd. on May 18, 2018 in Jungwon, Seongnam. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 3 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
May 18, 2018
Fiscal Year
2018
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Jungwon, Seongnam (Korea (the Republic of))

Citations

IDCFRDescription
111221 CFR 211.25(a)Training--operations, GMPs, written procedures
145021 CFR 211.113(a)Procedures for non-sterile drug products
357021 CFR 211.100(a)Approval and review of procedures